Fused benzo compounds of formula I are provided, wherein A is a 2 to 6 membered hydrocarbon spacer group, B is a polar divalent group selected from a group (a); U is C, N or CH; X is a divalent 3-4 membered chain optionally comprising one or more heteroatoms; R.sup.1 is an aliphatic hydrocarbon group, arylalkyl or diphenylalkyl; R.sup.2 and R.sup.3 are hydrogen or alkyl or together form an ethylene or propylene bridge; R.sup.4, R.sup.5 and R.sup.6 are hydrogen or substituents; R.sup.7 and R.sup.8 are hydrogen or substituents including --COOR.sup.9 and --CONR.sup.10 R.sup.11 ; are 5-HT.sub.1A receptor ligands useful in the treatment of CNS disorders. Pharmaceutical compositions comprising the compounds and their use for the manufacture of a pharmaceutical preparation are also provided.
提供了式I的融合苯并化合物,其中A是一个2到6个成员的碳氢化合物间隔基团,B是从组(a)中选择的极性二价基团;U是C、N或CH;X是一个二价的3-4个成员的链,可选地包括一个或多个杂原子;R.sup.1是一个脂肪烃基、芳基烷基或二苯基烷基;R.sup.2和R.sup.3是氢或烷基,或者一起形成一个
乙烯或
丙烯桥;R.sup.4、R.sup.5和R.sup.6是氢或取代基;R.sup.7和R.sup.8是氢或取代基,包括--COOR.sup.9和--CONR.sup.10 R.sup.11;是用于治疗中枢神经系统疾病的5-HT.sub.1A受体
配体。还提供了包含这些化合物的药物组合物以及它们用于制备药物制剂的用途。